Cronos Group (NASDAQ:CRON) Stock Rating Lowered by Wall Street Zen

Cronos Group (NASDAQ:CRON – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts also recently weighed in on CRON. Weiss Ratings upgraded shares of Cronos Group from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. TD Securities reiterated a “buy” rating on shares of Cronos Group in a research note on Monday, September 28th. Finally, Zacks Research raised Cronos Group from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $2.30.

View Our Latest Report on Cronos Group

Cronos Group Stock Down 1.3%

Shares of Cronos Group stock opened at $3.04 on Friday. Cronos Group has a twelve month low of $2.28 and a twelve month high of $3.91. The company has a 50-day simple moving average of $3.32 and a two-hundred day simple moving average of $2.91. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of 40.88 and a beta of 0.96.

Cronos Group (NASDAQ:CRON – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. Cronos Group had a net margin of 28.04% and a return on equity of 2.56%. The firm had revenue of $63.45 million during the quarter, compared to the consensus estimate of $51.15 million. On average, sell-side analysts anticipate that Cronos Group will post 0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Pure Financial Advisors LLC acquired a new position in Cronos Group during the second quarter worth about $28,000. OneDigital Investment Advisors LLC bought a new position in shares of Cronos Group in the second quarter worth about $29,000. Two Sigma Securities LLC bought a new position in shares of Cronos Group in the second quarter worth about $34,000. Concurrent Investment Advisors LLC boosted its stake in shares of Cronos Group by 69.0% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 19,623 shares of the company’s stock valued at $55,000 after purchasing an additional 8,009 shares in the last quarter. Finally, Amundi acquired a new stake in shares of Cronos Group in the 1st quarter valued at approximately $54,000. Institutional investors own 8.71% of the company’s stock.

About Cronos Group

(Get Free Report)

Cronos Group is a cannabinoid company that develops, produces, and markets cannabis and cannabis-derived products. Its business includes cultivation, processing, product development, and distribution. The company sells products in categories such as dried cannabis flower, pre-rolls, vaporizers, edibles, and extracts. Its brand portfolio includes Spinach and PEACE NATURALS. Founded in 2012 and headquartered in Toronto, Cronos serves consumers in Canada and select international markets, including Israel.

Featured Stories

Analyst Recommendations for Cronos Group (NASDAQ:CRON)

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.